2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

909. Medical Education and Workforce Development: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Treatment Considerations, Supportive Care, Biological Therapies, Bispecific Antibody Therapy, Women’s Health, Workforce, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Value, Diseases, Bleeding and Clotting, Hemoglobinopathies, Sickle Cell Disease, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, ALL, Research, Fundamental Science, Translational Research, Clinical Research, Health Outcomes Research, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Neonatal, Pregnant, Young Adult
PAPER

6372 Defining the impact of patient narratives in the pre-clerkship hematology curriculum on the medical student experience

Nisha Joseph, MD, Shaheen Rana, MA2, Mary Jo Lechowicz, MD3, David Schulman, MD4, Markie Zimmer, MD5, Ronak Mistry, DO6, Leslie Kersun7
1 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
2 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
3 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
4 Emory University School of Medicine, Atlanta, Georgia, United States
5 Henry Ford Hospital, Detroit, Michigan, United States
6 University of Pennsylvania, philadelphia, Pennsylvania, United States
7 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Background: Current literature strongly supports the value of patient interviews in pre-clerkship medical student education, finding that these experiences improve empathy and enhance students’ understanding of the disease. (Boshra et al, Can Med Educ J 2022) However, there are no published studies on the specific impact of patient interviews on the specific impact in medical student education in hematology. Here, we aim to better understand the unique impact of patient interviews on medical student hematology education and potentially further support more widespread incorporation of patient narratives into medical school hematology curricula. Conception and development of this study was guided by the ASH Medical Educators Institute program. 
Methods: During the three-week pre-clerkship hematology course held from May 26 to June 12, 2026 at the Emory University School of Medicine, there were three scheduled patient narrative sessions with the diagnoses of sickle cell disease, multiple myeloma with prior autologous stem cell transplant and acute leukemia with prior allogeneic stem cell transplant. Each session included a guided interview by the patient’s hematologist about their diagnosis, clinical course and perspective followed by an open question and answer session. Following the session, students were provided a QR code linked to an anonymous and voluntary survey with three open ended questions: (1) What did you find most impactful or surprising about what you heard today?, (2) Was there anything you heard today that might impact or change how you interact with patients and if so, briefly describe, and (3) Did this session give you a better understanding of the underlying disease, briefly expand if so. All first- year medical students (n=136) had the opportunity to participate. Open-ended survey questions were analyzed using a standard thematic analysis approach (Braun & Clark, 2006). Responses were coded using an inductive approach, with an analyst reading each response individually and generating codes to summarize responses. A second analyst reviewed the codes; for any discrepancies, consensus was reached via discussion. Codes were grouped into broader themes and student data were summarized, with illustrative quotes, into matrices by disease type to further identify patterns. Matrices were reviewed by two analysts and provided an audit trail to increase trustworthiness in the findings. 
Results: In total, there were 123 responses: 78 responses to survey 1, 11 responses to survey 2 and 34 responses to survey 3. There were seven dominant themes and five subthemes. The primary themes included standard concepts that have been previously reported in other areas of medical education including better understanding of disease treatment, better understanding of disease symptoms, increased understanding of the healthcare journey, and impact of the disease on patient quality of life. Several additional themes that were specific to chronic and life-threatening diseases characteristic of the field of hematology and hematologic oncology included the importance of advocating for one’s patients, value of imbuing hope into difficult conversations and gaining insight into positive patient outcomes with treatment.
Conclusions: In summary, this analysis validated previously published findings that patient narratives and interviews are an integral component of medical student education by engaging students in the impact of disease on the patient’s life and enhancing their empathy and understanding of the patient experience. Importantly, this study specifically highlights the gained insights into the challenging nature of hematologic disease, how these diseases impact daily life, the reality of how effective our treatments are and reduce the negative perception of malignant conditions, and the importance of a strong patient relationship with one’s hematologist. This study underscores the unique benefit of patient narratives specifically in hematology pre-clinical education and supports incorporation of these sessions into medical school hematology courses.
Nisha Joseph, MD: Janssen - Honoraria; Legend - Honoraria; BMS - Honoraria; Regeneron - Research Funding; Janssen - Research Funding; BMS - Research Funding; Novartis - Research Funding; BMS - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony)